Last reviewed · How we verify

Tucidinostat, Azacitidine combined with CHOP

Peking Union Medical College Hospital · Phase 3 active Small molecule

Tucidinostat, Azacitidine combined with CHOP is a Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen Small molecule drug developed by Peking Union Medical College Hospital. It is currently in Phase 3 development for Acute myeloid leukemia.

Tucidinostat is a histone deacetylase inhibitor, while Azacitidine is a hypomethylating agent, and CHOP is a chemotherapy regimen.

Tucidinostat is a histone deacetylase inhibitor, while Azacitidine is a hypomethylating agent, and CHOP is a chemotherapy regimen. Used for Acute myeloid leukemia.

At a glance

Generic nameTucidinostat, Azacitidine combined with CHOP
SponsorPeking Union Medical College Hospital
Drug classHistone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen
TargetHistone deacetylases, DNA methyltransferases
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Tucidinostat works by inhibiting histone deacetylases, which can lead to changes in gene expression. Azacitidine, on the other hand, works by inhibiting DNA methyltransferases, leading to hypomethylation of DNA. CHOP is a combination chemotherapy regimen consisting of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, and Prednisone, which targets rapidly dividing cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tucidinostat, Azacitidine combined with CHOP

What is Tucidinostat, Azacitidine combined with CHOP?

Tucidinostat, Azacitidine combined with CHOP is a Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen drug developed by Peking Union Medical College Hospital, indicated for Acute myeloid leukemia.

How does Tucidinostat, Azacitidine combined with CHOP work?

Tucidinostat is a histone deacetylase inhibitor, while Azacitidine is a hypomethylating agent, and CHOP is a chemotherapy regimen.

What is Tucidinostat, Azacitidine combined with CHOP used for?

Tucidinostat, Azacitidine combined with CHOP is indicated for Acute myeloid leukemia.

Who makes Tucidinostat, Azacitidine combined with CHOP?

Tucidinostat, Azacitidine combined with CHOP is developed by Peking Union Medical College Hospital (see full Peking Union Medical College Hospital pipeline at /company/peking-union-medical-college-hospital).

What drug class is Tucidinostat, Azacitidine combined with CHOP in?

Tucidinostat, Azacitidine combined with CHOP belongs to the Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen class. See all Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen drugs at /class/histone-deacetylase-inhibitor-and-hypomethylating-agent-chemotherapy-regimen.

What development phase is Tucidinostat, Azacitidine combined with CHOP in?

Tucidinostat, Azacitidine combined with CHOP is in Phase 3.

What are the side effects of Tucidinostat, Azacitidine combined with CHOP?

Common side effects of Tucidinostat, Azacitidine combined with CHOP include Fatigue, Nausea, Vomiting, Diarrhea, Anemia, Thrombocytopenia.

What does Tucidinostat, Azacitidine combined with CHOP target?

Tucidinostat, Azacitidine combined with CHOP targets Histone deacetylases, DNA methyltransferases and is a Histone deacetylase inhibitor and hypomethylating agent, chemotherapy regimen.

Related